CertaraCERT
CERT
About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Employees: 1,546
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
137% more call options, than puts
Call options by funds: $596K | Put options by funds: $251K
62% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 34
46% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 63
8% more funds holding
Funds holding: 222 [Q4 2024] → 240 (+18) [Q1 2025]
3.42% more ownership
Funds ownership: 72.27% [Q4 2024] → 75.69% (+3.42%) [Q1 2025]
3% less capital invested
Capital invested by funds: $1.24B [Q4 2024] → $1.21B (-$32.5M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
37%
upside
Avg. target
$15
47%
upside
High target
$16
56%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Keybanc Scott Schoenhaus | 47%upside $15 | Overweight Maintained | 14 Jul 2025 |
Morgan Stanley Sean Laaman | 56%upside $16 | Equal-Weight Assumed | 3 Jul 2025 |
Barclays Luke Sergott | 37%upside $14 | Overweight Upgraded | 8 May 2025 |
Financial journalist opinion
Based on 5 articles about CERT published over the past 30 days
Positive
Zacks Investment Research
8 hours ago
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
2 weeks ago
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Seeking Alpha
2 weeks ago
Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences
Certara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and growing client base drive consistent revenue growth, with software revenue accelerating thanks to the Chemaxon acquisition. Certara's financials are strong, with stable cash flow, a healthy balance sheet, and a price-to-book ratio below the sector average, suggesting undervaluation.
Neutral
GlobeNewsWire
3 weeks ago
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
Neutral
GlobeNewsWire
3 weeks ago
Certara Announces Expansion of Clinical Technology Collaboration with Merck
RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck's use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management.
Positive
The Motley Fool
1 month ago
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Neutral
Seeking Alpha
2 months ago
Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Joe Vruwink - Baird Scott Schoenhaus - KeyBanc Capital Markets David Windley - Jefferies Dan Leonard - UBS Jeff Garro - Stephens Christine Rains - William Blair Constantine Davides - Citizens Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2025 Earnings Conference Call.
Positive
Zacks Investment Research
2 months ago
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.10 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Certara Reports First Quarter 2025 Financial Results
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025.
Neutral
GlobeNewsWire
3 months ago
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Charts implemented using Lightweight Charts™